Aegis Therapeutics is a drug-delivery and drug-formulation technologies company commercializing its patented drug delivery and protein stabilization technologies through product specific licenses to leading pharmaceutical and biopharmaceutical companies.

Aegis News

Aegis Intravail® Technology Enhances Oral Bioavailability of Tableted OTC Drugs

SAN DIEGO, CA March 12, 2014/MarketWire– Aegis Therapeutics LLC’s Intravail® technology has been successfully formulated with phenylephrine in compressed tablets, dramatically improving oral bioavailability by more than 50%.  This is the first application of Intravail® in a solid dosage form. The Intravail formulation is compatible with current tableting processes employed for OTC and prescription drugs […]

Aegis Awarded Its First Patent for Oral Delivery of Nucleotide-Based Drugs with High Bioavailability

SAN DIEGO, CA February 5, 2014/MarketWire– Aegis Therapeutics LLC announced today that it has been awarded its first patent for oral delivery of nucleotide analog based drugs based upon Aegis’ patented Intravail® transmucosal absorption enhancer technology.   U.S. Patent No. 8,642,564 provides methods for oral delivery of nucleotide-oligomer analogs including anti-sense and RNA interference drugs.  Such […]

Aegis Therapeutics Celebrates 10th Anniversary

SAN DIEGO, CA October 28, 2013 — Aegis Therapeutics LLC is proud to announce it is celebrating its 10-year anniversary on October 31, 2013. Aegis was founded by a renowned group of successful biotech entrepreneurs from the San Diego area to commercialize proprietary technologies that solve some of the most pressing drug delivery problems for […]

Aegis Awarded Its First Patent for Non-Invasive Delivery of a Protein Drug to the Central Nervous System (CNS)

SAN DIEGO, CA October 9, 2013/MarketWired– Aegis Therapeutics LLC announced today that it has been awarded its first patent for non-invasive delivery of a protein drug to the central nervous system  (CNS).   U.S. Patent No. 8,551,468 provides drug compositions for non-invasive direct delivery of stabilized beta-interferon to the central nervous system via a simple metered […]

Aegis Technologies Providing Rapid Development of Super Generics

SAN DIEGO, CA September 4, 2013/PR Newswire – Two “super generic” drugs utilizing Aegis Therapeutics Intravail technology for treatment of migraine headaches and seizures are rapidly advancing through clinical trials under the FDA’s 505(b)2 pathway. Rapid relief of certain medical conditions is dependent upon early establishment of therapeutic blood levels of drug. Examples include drugs […]

Aegis Awarded 3rd Patent for Fast Acting Migraine Nasal Spray Treatment

Aegis’ Intravail® formulation of sumatriptan achieves therapeutic drug levels in approximately 2 to 3 minutes SAN DIEGO, CA Aug 13, 2013 — Aegis Therapeutics LLC announced today that it has been awarded a third patent for fast acting formulations of triptans, a widely used class of drugs including sumatriptan, zolmitriptan, naratriptan, rizatriptan, eletriptan, almotriptan and […]

Biosimilars, Oxidative Damage, and Unwanted Immunogenicity Now Available Online

SAN DIEGO, CA August 12, 2013 –The article titled “Biosimilars, Oxidative Damage, and Unwanted Immunogenicity” published in Bioprocess International is now available online and as a downloadable PDF. The article highlights the fact that unwanted immunogenicity is an underlying cause of multiple deleterious effects for many protein-based therapeutics — including loss of efficacy, altered pharmacokinetics, […]

Aegis Therapeutics Launches New Website

SAN DIEGO, CA  August  7, 2013 – Aegis Therapeutics LLC is happy to announce the launching of our updated website. The new website provides expanded technology and business related information relating to the Aegis Intravail®, ProTek®, and Aegis HydrogelTM  technologies, along with some publications explaining how our technologies work and how they may be used […]

Aegis Awarded Patent for Transdermal or Transmucosal Absorption Enhancement for Peptide and Small Molecule Drugs Employing Aegis’ Patented Self-Assembling Thixotropic Aqueous Hydrogels

SAN DIEGO, CA July 8, 2013/MarketWire– Aegis Therapeutics LLC announced today that it has been awarded U.S. Patent No. 8,470,370 providing proprietary methods for sustained release, transdermal, or transmucosal absorption enhancement for peptide and small molecule drugs using Aegis patented absorption-enhancing self-assembling aqueous hydrogels. The Aegis Hydrogels™ serve simultaneously as both delivery vehicle and absorption […]

Aegis Awarded 2nd Patent for Fast Acting Migraine Nasal Spray Treatment – Aegis' Intravail® formulation of sumatriptan achieves therapeutic drug levels in approximately 2 to 3 minutes

SAN DIEGO, CA May 14, 2013/PR Newswire — Aegis Therapeutics LLC announced today that it has been awarded U.S. Patent No. 8,440,631, its second patent providing fast acting formulations for triptans, a class of drugs that are effective in treating migraine headaches which include sumatriptan, zolmitriptan, naratriptan, rizatriptan, eletriptan, almotriptan and frovatriptan.  Human clinical trials […]